首页
订购/客服:400-666-5481

JNJ-10198409

    
99.70%

N-(3-fluorophenyl)-1,4-dihydro-6,7-dimethoxy-indeno[1,2-c]pyrazol-3-amine

源叶(MedMol)
Y49017 一键复制产品信息
627518-40-5
C18H16FN3O2
325.34
3-氟-N-(6,7-二甲氧基-2,4-二氢茚并[1,2-c〕吡唑-3-基)苯基胺;JNJ-10198409; JNJ 10198409; JNJ10198409; RWJ-540973; RWJ 540973; RWJ540973
货号 规格 价格 上海 北京 珠海 重庆 武汉 购买数量
Y49017-5mg买3赠1
99.70%

¥800.00

9 - - - -
Y49017-25mg促销
99.70%

¥1970.00 ¥1570.00

8 - - - -
Y49017-100mg促销
≥98%

¥4070.00 ¥3250.00

货期:2-3天 - - - -
Y49017-1g促销
≥98%

¥16000.00 ¥12800.00

货期:2-3天 - - - -
产品介绍 参考文献 质检证书(COA) 摩尔浓度计算器 相关产品
产品描述: JNJ-10198409 is a relatively selective, orally active, and ATP competitive PDGF-RTK (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC50=2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM)
靶点: PDGFRβ:4.2 nM (IC50);PDGFRα:45 nM (IC50);PDGFR
体外研究: JNJ-10198409 has potent antiproliferative activity in six of eight human tumor cell lines (IC50<0.033 μM) and is a potent inhibitor of the c-Abl kinase (IC50=22 nM)
参考文献: 1. D'Andrea MR, et al. Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis. Mol Cancer Ther. 2005 Aug;4(8):1198-204. 2. Ho CY, et al. (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. J Med Chem. 2005 Dec 29;48(26):8163-73.
溶解性: Soluble  in  DMSO
保存条件: -20℃
配置溶液浓度参考:
1mg 5mg 10mg
1 mM 3.074 ml 15.369 ml 30.737 ml
5 mM 0.615 ml 3.074 ml 6.147 ml
10 mM 0.307 ml 1.537 ml 3.074 ml
50 mM 0.061 ml 0.307 ml 0.615 ml
注意: 部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。

参考文献

质检证书(COA)

如何获取质检证书(COA)?
请输入货号和一个与之匹配的批号。
例如:
批号:JS298415 货号:S20001-25g
在货品标签上如何找到货号和批号?

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

=
×
×